Your browser doesn't support javascript.
Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies.
Yetmar, Zachary A; Khodadadi, Ryan B; Seville, Maria Teresa; Brumble, Lisa; O'Horo, John C; Ganesh, Ravindra; Razonable, Raymund R.
  • Yetmar ZA; Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
  • Khodadadi RB; Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
  • Seville MT; Division of Infectious Diseases, Mayo Clinic, Scottsdale, Arizona, USA.
  • Brumble L; Division of Infectious Diseases, Mayo Clinic, Jacksonville, Florida, USA.
  • O'Horo JC; Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
  • Ganesh R; Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Razonable RR; Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Open Forum Infect Dis ; 9(7): ofac204, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1922311
ABSTRACT
Antispike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate coronavirus disease 2019 (COVID-19) resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Antispike monoclonal antibodies appear effective in this immunocompromised population.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Long Covid Language: English Journal: Open Forum Infect Dis Year: 2022 Document Type: Article Affiliation country: Ofid

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Long Covid Language: English Journal: Open Forum Infect Dis Year: 2022 Document Type: Article Affiliation country: Ofid